Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)

NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable in adults. This is because Merck Sharp & Dohme did not provide a complete evidence submission.

Last reviewed: 17 February 2021

This advice updates and replaces NICE technology appraisal guidance 522 on pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable, which was available through the Cancer Drugs Fund. People already taking it will be able to continue until they and their doctor decide when best to stop.

Next review: We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance